Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth

Sandra E. Pike, Lei Yao, Karen D. Jones, Barry Cherney, Ettore Appella, Kazuyasu Sakaguchi, Hira Nakhasi, Julie Teruya-Feldstein, Peter Wirth, Ghanshyam Gupta, Giovanna Tosato

Research output: Contribution to journalArticlepeer-review

281 Scopus citations


An endothelial cell inhibitor was purified from supernatant of an Epstein-Barr virus-immortalized cell line and identified as fragments of calreticulin. The purified recombinant NH2-terminal domain of calreticulin (amino acids 1-180) inhibited the proliferation of endothelial cells, but not cells of other lineages, and suppressed angiogenesis in vivo. We have named this NH2-terminal domain of calreticulin vasostatin. When inoculated into athymic mice, vasostatin significantly reduced growth of human Burkitt lymphoma and human colon carcinoma. Compared with other inhibitors of angiogenesis, vasostatin is a small, soluble, and stable molecule that is easy to produce and deliver. As an angiogenesis inhibitor that specifically targets proliferating endothelial cells, vasostatin has a unique potential for cancer treatment.

Original languageEnglish
Pages (from-to)2349-2356
Number of pages8
JournalJournal of Experimental Medicine
Issue number12
StatePublished - 1998
Externally publishedYes


  • Angiogenesis
  • Antitumor agent
  • Cancer
  • Cell growth
  • Endothelial cells


Dive into the research topics of 'Vasostatin, a calreticulin fragment, inhibits angiogenesis and suppresses tumor growth'. Together they form a unique fingerprint.

Cite this